Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

The asthma medication reduces congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in a ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8527 ...

Nasal Polyps Treatment Market Research Report The global nasal polyps treatment market is expected to reach around $4,243.9 million by 2030 ...

Neffy (epinephrine nasal spray) 1mg is approved for the emergency treatment of type 1 allergic reactions in children aged 4 ...

Silent rhinovirus (RV) infection is prevalent in nasal tissues and is associated with distinct immune responses in those with and without chronic rhinosinusitis with nasal polyps (CRSwNP). These were ...

Cash and cash equivalents as of December 31 were $40.6M compared with cash, cash equivalents and short-term investments of $51.6M at ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...

Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the ...